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Objective
To validate the methodology of isolated hypoxic hepatic perfu-
sion (IHHP) using balloon catheter techniques and to gain insight
into the distribution of tumor necrosis factor-alpha (TNF), mel-
phalan, and mitomycin C (MMC) through the regional and sys-
temic blood compartments when applying these techniques.
Summary Background Data
There is no standard treatment for unresectable liver tumors.
Clinical results of isolated limb perfusion with high-dose TNF
and melphalan for the treatment of melanoma and sarcoma
have been promising, and aftempts have been made to ex-
trapolate this success to the isolated liver perfusion setting.
The magnitude and toxicity of the surgical procedure, how-
ever, have limited clinical applicability.
Methods
Pigs underwent IHHP with TNF, melphalan, and MMC using
balloon catheters or served as controls, receiving equivalent
dosages of these agents intravenously. After a 20-minute per-
fusion, a washout procedure was performed for 10 minutes,
after which isolation was terminated. Throughout the proce-
dure and afterward, blood samples were obtained from the
hepatic and systemic blood compartments and concentra-
tions of perfused agents were determined.
Results
During perfusion, locoregional plasma drug concentrations
were 20- to 40-fold higher than systemic concentrations.
Compared with systemic concentrations after intravenous
administration, regional concentrations during IHHP were up
to 1 0-fold higher. Regional MMC and melphalan levels
steadily declined during perfusion, indicating rapid uptake by
the liver tissue; minimal systemic concentrations indicated
virtually no leakage to the systemic blood compartment. Dur-
ing isolation, concentrations of TNF in the perfusate declined
only slightly, indicating limited uptake by the liver tissue; no
leakage of TNF to the systemic circulation was observed. Af-
ter termination of isolation, systemic TNF levels showed only a
minor transient elevation, indicating that the washout proce-
dure at the end of the perfusions was fully effective.
Conclusions
Complete isolation of the hepatic vascular bed can be ac-
complished when performing IHHP using this balloon catheter
technique. Thus, as in extremities, an ideal leakage-free perfu-
sion of the liver can now be performed, and repeated, without
major surgery. The effective washout allows the addition of
TNF in this setting.
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The importance of developing new treatment modalities
for primary and secondary liver tumors is evident. Hepato-
cellular carcinoma is one of the most common malignant
tumors in the world today; it develops in approximately 1
million persons each year.1 Recent advances in early detec-
tion have improved the prognosis.2 In general, however,
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tumors are not resectable at the time of diagnosis, and the
prognosis of hepatocellular carcinoma remains poor.3 The
liver is a major site of metastatic spread of primary colo-
rectal cancer, and it is the sole site of initial tumor recur-
rence in as many as 30% of patients.4 Patients with resect-
able liver metastases can be cured by surgery, with reported
5-year survival figures ranging from 16% to 45%.57 How-
ever, in 75% of patients with colorectal cancer metastases
confined to the liver, these metastases are considered unre-
sectable. Because the main determinant for duration of
survival in these numerous patients is local tumor progres-
sion, new treatment modalities and'schedule-s;'must be aimned
at achieving local tumor control.
For most chemotherapeutic agents, steep dose-response
curves can be demonstrated. Therefore, high drug concen-
trations are important for eradicating both sensitive and
resistant tumor cells.48 Systemic chemotherapy results in
relatively low response rates both for colorectal liver me-
tastases and primary liver tumors and has minimal effects
on survival.9
The main principle of isolated regional chemotherapy is
to achieve higher regional drug concentrations and thus
higher exposure of tumor tissue to the agents, resulting in
increased response rates, while shielding the organism from
the systemic toxicity because of the much lower concentra-
tions in the systemic circulation. These principles are even
more important for the potential application of tumor ne-
crosis factor-alpha (TNF). The toxicity of this cytokine has
made systemic application of adequate doses with antitumor
effect impossible.'0'11 However, in a leakage-free isolated
perfusion setting, it can be safely used with remarkable
results. Response rates of >80% have been observed in the
treatment of unresectable extremity soft-tissue sarcomas
using isolated limb perfusion with TNF plus melphalan.12'13
In the wake of these promising clinical results, efforts
have been made to translate this success to other regional
perfusion settings. The liver is one of the most obvious
targets, and successful isolated perfusions of the liver with
cytostatic drugs, both in animal models and in humans, have
been reported. 14-16 The applicability of TNF in the setting
of leakage-free isolated liver perfusion has been reported by
teams from the National Cancer Institute and by us.17-19
Major drawbacks of clinical application, however, are the
magnitude and associated toxicity of the surgical procedure
and the complexity and costs of using a venous bypass
system as well as a heart-lung machine operated by a team
of perfusionists.19 For this concept to become practical in a
clinical setting, less invasive alternatives must be devel-
oped. Thus, if isolated liver perfusion is to become a treat-
ment option applicable on a large scale, the extent, compli-
cations, and costs of the intervention must be acceptable,
and the procedure should be repeatable and yield good
response rates. Several groups have reported on regional
arterial infusion of chemotherapeutic drugs in combination
with complete or incomplete hepatic venous isolation; how-
ever, these procedures were combined with hemofiltration
systems.2022
New balloon catheter techniques allow relative vascular
isolation of the abdomen and pelvis with only minimally
invasive surgery.2325 Several authors have published arti-
cles on these methods and have used aortic hypoxic perfu-
sion chemotherapy for unresectable tumors confined to the
pelvis or abdomen.2628 Hypoxia causes dividing cells to
halt their progression through the cell cycle by allowing
them to progress to and then remain in the GI-like suscep-
tibility state.29 Drugs whose cytotoxic action is particularly
*potentiatedby hypQxia, such.as, mitomycin C (MMC) and
melphalan, have been reported to be particularly effective
when administered by aortic stop-flow infusion.26'27'30
With the use of a caval double-balloon catheter for com-
plete venous isolation of the liver, in combination with an
aortic occlusion catheter and a port catheter placed in the
gastroduodenal artery, it has become a relatively simple
procedure to perform an isolated liver perfusion. We tested
the feasibility and quality of this approach and report here
on this methodology and its validation by studying the
distribution of TNF, melphalan, and MMC through the
regional and systemic blood compartments in pigs.
MATERIALS AND METHODS
Animals
Dutch Yorkshire pigs weighing 30 to 40 kg were used.
Animals were treated in compliance with the guidelines on
animal welfare of the Erasmus University, Rotterdam. The
study protocol was approved by the Ethics Committee on
Experimental Studies in Animals of the Erasmus Univer-
sity, Rotterdam.
Drugs
Recombinant human (4.9 to 5.8 X 107 units/mg) was
provided as a kind gift by Boehringer Ingelheim GmbH,
Ingelheim/Rhein, Germany. Melphalan (L-pam, Alkeran,
Wellcome Ltd., London, UK) was obtained as a sterile
powder (100 mg) that was dissolved aseptically using sol-
vent and diluent provided by Burroughs Wellcome (Lon-
don, UK). MMC (Kyowa Hakko Kogyo Co. Ltd., Tokyo,
Japan) was obtained as a sterile powder (40 mg) that was
dissolved aseptically in 40 ml saline 0.9%.
Perfusion Set
Perfusion sets were kindly provided by PfM GmbH (Co-
logne, Germany) and consisted of a double-balloon catheter
(12F, balloon capacity 25 ml, distance between balloons 4
cm) for venous isolation of the liver, an aortic occlusion
balloon catheter (12F, balloon capacity 25 ml) for compen-
sating the decrease in cardiac preload during the procedure,
and a tubing set with a volume of 220 ml containing a
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Figure 1. An isolated hypoxic hepatic perfusion with balloon catheter
techniques.
bubble trap. In the perfusion circuit, flow was maintained by
a roller pump, and the temperature of the perfusate was
regulated by a heat exchanger (Cardioplegia heat ex-
changer, CSC14 Sorin, Biomedica, Italy). Drugs were in-
fused through a sideline into the perfusion circuit.
Surgical Procedure
Figure 1 illustrates the methodology of an isolated hy-
poxic hepatic perfusion (IHHP) with balloon catheters. It
shows the position of the occlusion catheters, the inflow
catheter in the gastroduodenal artery, and the other compo-
nents of the perfusion circuit. The IHHP procedure was
carried out as follows. General anesthesia was induced in
pigs by standard methods and maintained with pancuronium
and fentanyl. An arterial line was introduced into a carotid
artery and a double-lumen central venous catheter was
placed in an external jugular vein on either side. After a
midline laparotomy was performed, the gastroduodenal or
common hepatic artery was cannulated with the arterial
infusion catheter (7F). Pigs were subsequently heparinized
with 2 mg/kg heparin. After formal surgical exposure of the
femoral vessels, the aortic occlusion catheter was intro-
duced into the common femoral artery. Subsequently the
double-balloon catheter was introduced into the common
femoral vein and retrogradely moved up into the caval vein,
positioning the balloons above and below the hepatic veins.
To compensate for the decrease in cardiac preload, the aorta
was clamped or the aortic occlusion balloon was inflated.
Caval balloons were then inflated and temporary isolation of
the hepatic vascular bed was obtained by clamping the
hepatic artery and subsequently the portal vein. After con-
necting the double-balloon catheter and arterial cannula to
the perfusion system primed with 220 ml Haemaccel (Be-
hring Pharma, Amsterdam, The Netherlands), the perfusate
was circulated by means of a roller pump with a constant
flow of 200 ml/minute. The temperature of the perfusate
was kept at 38.5°C by means of a heat exchanger. Stable
perfusion was assessed by monitoring the blood level in the
bubble trap.
Drugs were rapidly administered as a bolus infusion into
the perfusate. After 20 minutes of perfusion, the remaining
agents were washed out of the hepatic vascular bed by
perfusing the isolated circuit with Haemaccel for 10 minutes
and collecting the venous effluent. Isolation was then ter-
minated by releasing the temporary clamps on the portal
vein and the hepatic artery, and the caval balloons and the
aortic balloon were deflated. The total time of clamping the
portal vein did not exceed 35 to 40 minutes.
Control animals were given an equivalent amount of
drugs as a bolus injection through a central venous line
placed in the external jugular vein. Samples were obtained
from a carotid arterial line.
Blood Sampling
Baseline blood samples were obtained before administra-
tion of the drugs into the regional circuit. Throughout and
after the procedure, blood samples were simultaneously
drawn from the hepatic blood compartment through a sam-
pling port on the caval double-balloon catheter and from the
systemic blood compartment through the central venous
catheter at 5, 10, 15, 20 (before washout started), 30 (before
termination of isolation), 35, 55, and 85 minutes after infu-
sion of the agents. Blood samples of animals that received
the drugs as an intravenous bolus infusion were drawn at 5,
10, 15, 20, 25, 35, 55, 85, 150, and 180 minutes after
administration. Blood samples were collected in glass tubes
containing EDTA and immediately stored in the dark on ice.
Samples were centrifuged at 2600 r.p.m. for 6 minutes at
4°C, and the obtained plasma was stored at -70°C until
analysis.
Treatment Schedule
Five pigs underwent IHHP and five pigs received the
drugs as an intravenous bolus infusion. Of the group that
underwent IHHP, two pigs were given MMC (0.25 mg/kg)
and melphalan (0.25 mg/kg) alone, and three pigs were
given the same amount of MMC and melphalan in combi-
nation with TNF (0.02 mg/kg). Of the pigs that received an
intravenous bolus, two were given MMC (0.25 mg/kg) and
melphalan (0.25 mg/kg) alone, and three were given the
same amount of MMC and melphalan in combination with
TNF (0.02 mg/kg).
Bioanalysis
Plasma TNF concentrations were determined using
ELISA for rhTNF as described by Engelberts et al.3' In
short, a 96-well Immuno-Maxisorp plate was coated with
murine antihuman TNF mAb 61E71. A standard titration
curve was obtained by making serial dilutions of a known
sample of human rhTNF in normal porcine serum. The
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plates were incubated with a polyclonal rabbit antihuman
TNF antiserum, followed by addition of an enzyme-labeled
antirabbit reagent and enzyme reaction. The detection limit
for human TNF was 20 pg/ml.
Melphalan in plasma was measured by gas chromatogra-
phy/mass spectrometry. P-[Bis(2-chloroethyl)amino]-phe-
nylacetic acid methyl ester was used as an internal standard.
Samples were extracted over trifunctional C18 silica col-
umns. After elution with methanol and evaporation, the
compounds were derivatized with trifluoroacetic anhydride
and diazomethane in ether. The stable derivatives were
separated on a methyl phenyl siloxane GC capillary column
and measured selectively by single ion monitoring mass
spectrometry in the positive El mode. The detection limit
for melphalan is 10 pg/ml. Details of this assay were de-
scribed by us.32
Concentrations of MMC were analyzed by high-perfor-
mance liquid chromatography with ultraviolet detection.
Porfiromycin was used as an internal standard. Samples
were extracted over XAD-2 columns. After elution with
methanol and evaporation, the dry residue was diluted in the
mobile phase, which consisted of methanol and water (40/60).
The sample was injected and separated over a C18 column
and detected at 362 nm. The detection limit for MMC is 10
pg/ml. Details of the assay are described elsewhere.33
Calculation of Area Under the Curve
Areas under the plasma concentration versus time curve
(AUCs) were calculated applying the trapezoid rule using
GraphPad Prism software. AUCs were calculated from 5 to
20 minutes after the start of perfusion or from 5 to 20
minutes after administration of the intravenous bolus.
RESULTS
All pigs survived the procedures. Data were obtained
from five subsequent procedures. Apart from transient
tachycardia in a minority of pigs, stable hemodynamics
were observed throughout the procedures. After deflating
the balloons, a short period of hypotension was observed,
easily managed by fluid challenge. The addition of TNF to
MMC and melphalan did not alter the plasma concentration
versus time profile of MMC and melphalan during and after
the procedure (data not shown). Therefore, data from pigs
perfused with melphalan and MMC alone and from pigs
perfused with melphalan and MMC plus TNF were pooled.
Plasma Concentrations
Figure 2 shows the mean systemic plasma concentrations
of MMC, melphalan, and TNF after administration of these
agents as an intravenous bolus. A typical one-phase expo-
nential decay curve was observed for TNF and MMC with
an elimination half-life of 31 minutes for TNF and 7.2
minutes for MMC. Two-phase exponential decay was ob-
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Figure 2. Plasma concentration curves after intravenous bolus injec-
tions of melphalan (0.25 mg/kg) (A), mitomycin C (0.25 mg/kg) (B), and
tumor necrosis factor-alpha (0.02 mg/kg) (C). For mitomycin C and
melphalan, mean plasma concentrations of five pigs ± SEM are shown.
For tumor necrosis factor-alpha, mean plasma concentrations of three
pigs ± SEM are shown.
served for melphalan with a Al of 2.8 and a A2 of 161
minutes.
During perfusion, concentrations of MMC and melphalan
were markedly greater in the isolated hepatic vascular com-
partment than in the systemic compartment (Fig. 3). After 5
minutes of perfusion, mean MMC peak levels were 38-fold
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Figure 4. Regional (black circles) and systemic (white circles) plasma
concentration curves throughout and after 20 minutes of isolated hy-
b poxic hepatic perfusion with tumor necrosis factor-alpha (0.02 mg/kg).
Perfusion was followed by a 10-minute washout. Mean plasma con-
centrations of three pigs ± SEM are shown.
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Figure 3. Regional (black circles) and systemic (white circles) plasma
concentration curves throughout and after 20 minutes of isolated hy-
poxic hepatic perfusion with melphalan (0.25 mg/kg) (A) and mitomycin
C (0.25 mg/kg) (B). Perfusion was followed by a 10-minute washout.
Mean plasma concentrations of five pigs ± SEM are shown.
using values of drug concentrations from 5 to 20 minutes.
Much higher AUCs were found during IHHP for the iso-
lated hepatic vascular compartment than for the systemic
compartment, or as compared with plasma levels after ad-
ministration of an intravenous bolus. Regional drug concen-
tration versus time advantages of 20- to 40-fold were ob-
served during IHHP (melphalan, 20.4; MMC, 27.9; TNF,
43.3). When regional AUCs were compared with systemic
AUCs after systemic bolus administration of equivalent
doses, regional advantages varied from 3.2 to 11.5 (TNF,
3.2; MMC, 3.6; melphalan, 11.5).
higher than systemic peak MMC plasma concentrations (2222
ng/ml vs. 59 ng/ml). Mean melphalan peak levels at 5 minutes
were 33-fold higher than mean systemic plasma concentrations
(3028 ng/ml vs. 93 ng/ml). During the 20 minutes of perfusion,
MMC and melphalan plasma levels in the isolated hepatic
vascular compartment steadily declined. However, systemic
levels of melphalan and MMC remained at <93 ng/ml and 59
ng/ml, respectively, throughout the procedure, indicating no
significant leakage from the isolated circuit.
The mean plasma concentration of TNF at 5 minutes was
840 ng/ml; it remained virtually stable throughout perfu-
sion, not exhibiting the regional concentration decline ob-
served for MMC and melphalan (Fig. 4). Systemic TNF
concentrations remained at <22 ng/ml throughout the 20
minutes of perfusion. As a result of the washout procedure,
regional TNF concentrations declined from 648 ng/ml to 99
ng/ml. Five minutes after termination of isolation, systemic
TNF levels showed only a small rise to 50 ng/ml.
Areas Under the Curve
Table summarizes the regional versus systemic ratios
for TNF, MMC, and melphalan. AUCs were calculated
DISCUSSION
We have demonstrated in this series of experiments in
pigs the feasibility and safety of a leakage-free IHHP using
balloon catheter methodology. Regionally, tissue exposure
Table 1. AREA UNDER THE
CONCENTRATION VERSUS TIME CURVE
AND RATIOS DURING ISOLATED
HYPOXIC HEPATIC PERFUSION IN PIGS
AUC (ng x min/m) Melphalan MMC TNF
Regional*
Systemict
Intravenoust
AUC ratios
Regiona/systemic
Regional/intravenous
26860
1319
2339
20.4
11.5
16940
608
4657
27.9
3.6
11340
262
3528
43.3
3.2
* Regional is regional plasma concentration in isolated hepatic vascular blood-
compartment during IHHP.
t Systemic is systemic plasma concentration during IHHP.
t Intravenous is systemic drug concentrations after intravenous bolus administra-
tion.
AUC was calculated between t = 5 and t = 20 minutes after start of perfusion.
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to perfused drugs was 20 to 40 times greater than systemic
exposure. Because of the leakage-free quality of the
method, these ratios are just as good as those observed with
classic surgical isolated liver perfusions.'7"8'34 Regional
MMC and melphalan levels declined rapidly during perfu-
sion, indicating a fast uptake by the liver tissue; concomitant
minimal systemic concentrations indicated virtually no
leakage to the systemic blood compartment. This holds true
not only for the parent drugs, but also for possible toxic
metabolites and degradation products.32 During isolation,
concentrations of TNF in the perfusate declined only
slightly, indicating limited uptake by the liver tissue; no
leakage of TNF was observed. After termination of isola-
tion, systemic TNF levels showed only a minor transient
elevation, indicating that the washout procedure at the end
of the perfusion was fully effective.
One could argue that regional/intravenous AUC ratios
(see Table 1) become less favorable if they are calculated
over the time period from 0 to 180 minutes instead of over
the time period of isolation. For instance, calculated re-
gional/intravenous ratios for melphalan, MMC, and TNF
would become 7, 13, and 1, respectively. However, the high
concentrations of TNF that are maintained during isolation
have a different effect35: the high concentrations have been
shown to have vascular toxicity but are necessary to obtain
an optimal effect,36 thus promoting enhanced uptake of
MMC and melphalan. It is important that high concentra-
tions are achieved for a short period, because in previous
studies by us in patients with isolated limb perfusion, im-
mediate TNF-induced vascular leakage was observed.37
Isolated hepatic perfusion has been developed as a treat-
ment modality that maximizes drug concentrations in the
target organ while shielding the organism from systemic
toxicity.'4-16 It is a means to improve the selectivity of
administration of antitumor agents to the liver, as compared
with hepatic artery infusion (HAI). When MMC was ad-
ministered by IHP, a fourfold higher dose could be safely
administered; this resulted in a tumor tissue concentration
five times greater than that of HAI.38 Similar results were
obtained with melphalan.39 The relative pharmacologic ad-
vantage of IHHP for MMC in our experiments may seem
relatively small when compared with HAI with MMC.
However, in IHHP the dose of MMC can be increased and
the exposure time can be prolonged, whereas these param-
eters cannot be further exploited with HAI. It is clear from
experimental data that in this setting liver toxicity rather
than systemic toxicity is dose-limiting.34'38 In earlier exper-
iments, we performed classic isolated hepatic perfusion on
pigs with melphalan and TNF for 90 minutes. In these
experiments a transient elevation of liver enzyme levels
reflected acute but overall moderate toxicity; no late toxicity
was observed.'7
Clinical experience with isolated hepatic perfusion is
limited. Aigner40 treated patients using classic surgical iso-
lated hepatic perfusion chemotherapy, reporting 5-year sur-
vival rates of >10%. However, classic procedures have
been associated with significant mortality and morbidity
rates of > 10%164142
The development of balloon catheter-mediated IHHP rep-
resents a significant improvement over the classic procedure
in four ways. First, it limits the scale of the procedure and
thus reduces the associated complications and high costs.
IHHP, using described techniques, takes about 2 hours; the
classic procedure takes an average of >6 hours,'7 which in
patients was found to be associated with a high morbidity
rate.'8"19 Moreover, IHHP is less costly in terms of person-
nel (no perfusionists required) and material (no heart-lung
machine or portocaval venous bypass). Second, IHHP is a
technique that in principle allows for repeated isolated per-
fusions when the arterial infusion catheter is left in place
after the first perfusion and connected to a subcutaneous
port. This is of particular importance because multiple treat-
ments are needed to keep the disease in the liver under
control. Third, IHHP makes use of hypoxia, which renders
tumor cells more sensitive to cytostatic agents in general
and enhances in particular the antitumor effects of drugs
such as MMC and melphalan.29'30
Finally, by limiting the extent of the surgical intervention,
while still achieving full isolation and thus allowing com-
plete washout of perfused agents after perfusion, IHHP in
theory makes possible the introduction of drugs such as
TNF. This is important because the combination ofTNF and
melphalan has been shown to exert highly synergistic anti-
tumor effects against otherwise resistant tumors such as
soft-tissue sarcomas and melanoma in the setting of isolated
limb perfusion. Therefore, IHHP facilitates the translation
of the successful experience with TNF in isolated limb
perfusion into its application in isolated hepatic perfusion.
The pharmacokinetic profiles of TNF, MMC, and mel-
phalan in balloon catheter-mediated isolated pelvic and
abdominal perfusions have been virtually identical in our
experience in pigs43 and in humans (manuscript in prepa-
ration). Therefore, we are confident that a similar correla-
tion will exist between the pharmacokinetic profiles of these
agents during IHHP in pigs and those that will be obtained
in patients in a phase I-II study we have recently started in
our clinic.
A crucial point in cancer therapy is to use the right drug
in the right patient. A promising substance with important in
vitro and in vivo antitumor effects is TNF.8'44 Because of
its general toxicity, however, TNF cannot be given in ade-
quate doses intravenously.'0"'1 When administered at ade-
quate concentrations, such as in isolated limb perfusions, it
is effective in humans. 12,13,45,46 High doses of TNF can
induce tumor necrosis with acute softening of the tumor
brought about by selective destruction of the tumor's mi-
crovasculature, causing acute hemorrhagic necrosis of the
tumor.12,35,4748 TNF can be used in high doses in the
extremity perfusion setting because leakage to the systemic
circulation is usually limited to 0% to 10%, and in theory
similar doses could be used in IHHP because a complete
washout of agents can be achieved. Hepatic toxicity, how-
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ever, is expected to be the dose-limiting factor. This was
indicated by the experience of Fraker and Alexander'8'49 at
the National Cancer Institute with classic isolated hepatic
perfusions: responses were achieved in about 75% of the
patients, which corresponds with our limited clinical expe-
rience with classic isolated hepatic perfusion with TNF and
melphalan. 19
In conclusion, we have demonstrated that IHHP has fa-
vorable pharmacokinetic characteristics for both TNF and
cytostatic agents that equal those that can be achieved by the
major procedure of a classic surgical isolated liver perfu-
sion. Moreover, the balloon catheter procedure can be re-
peated, which is of eminent importance in prolonging con-
trol of metastatic disease in the liver. IHHP may provide a
new chance to reintroduce TNF into the clinical setting in an
attempt to translate its success in combination with chemo-
therapy in isolated limb perfusions into the treatment of the
much more common problem of managing unresectable
malignant disease to the liver.
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